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Background: The Aim of this study is to study the minimum zinc dependent metalloprotease catalytic folding motif,
helix B Met loop-helix C, with proteolytic catalytic activities in metzincin super family. The metzincin super family share a
catalytic domain consisting of a twisted five-stranded β sheet and three long α helices (A, B and C). The catalytic zinc is at
the bottom of the cleft and is ligated by three His residues in the consensus sequence motif, HEXXHXXGXXH, which is
located in helix B and part of the adjacent Met turn region. An interesting question is - what is the minimum portion of
the enzyme that still possesses catalytic and inhibitor recognition?”
Methods: We have expressed a 60-residue truncated form of matrilysin which retains only the helix B-Met turn-helix C
region and deletes helix A and the five-stranded β sheet which form the upper portion of the active cleft. This is only 1/4
of the full catalytic domain. The E. coli derived 6 kDa MMP-7 ZBD fragments were purified and refolded. The proteolytic
activities were analyzed by Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 peptide assay and CM-transferrin zymography analysis.
SC44463, BB94 and Phosphoramidon were computationally docked into the 3day structure of the human MMP7 ZBD
and TAD and thermolysin using the docking program GOLD.
Results: This minimal 6 kDa matrilysin has been refolded and shown to have proteolytic activity in the Mca-Pro-Leu
-Gly-Leu-Dpa-Ala-Arg-NH2 peptide assay. Triton X-100 and heparin are important factors in the refolding environment
for this mini-enzyme matrilysin. This minienzyme has the proteolytic activity towards peptide substrate, but the
hexamer and octamer of the mini MMP-7 complex demonstrates the CM-transferrin proteolytic activities in
zymographic analysis. Peptide digestion is inhibited by SC44463, specific MMP7 inhibitors, but not phosphorimadon.
Interestingly, the mini MMP-7 can be processed by autolysis and producing~ 6~ 7 kDa fragments. Thus, many of the
functions of the enzyme are retained indicating that the helix B-Met loop-helix C is the minimal functional “domain”
found to date for the matrixin family.
Conclusions: The helix B-Met loop-helix C folding conserved in metalloprotease metzincin super family is able to
facilitate proteolytic catalysis for specific substrate and inhibitor recognition. The autolysis processing and producing
6 kDa mini MMP-7 is the smallest metalloprotease in living world.
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Matrix metalloproteases, or matrixins, are a family of cal-
cium and zinc-dependent metalloenzymes that degrade a
great variety of extracellular matrix components. The
matrixins are part of a large family, the “metzincin” family,
which includes Family M10 (matrixins and serralysins)
and Family M12 (astacins and reprolysins). All four groups
share the consensus zinc-binding sequence and Met-turn,
which forms the base of the binding pocket. These 4
groups are not closely related by sequence identity, and it
is their protein fold that first led to their assignment to a
single metzincin group. The active centers have in com-
mon the characteristic HEXXHXXGXXH zinc-binding
motif located in helix-2 (Table 1) [1]. Three histidine resi-
dues serve as zinc ligands, and the glutamic acid residue
polarizes a water molecule involved in the nucleophilic at-
tack on the scissile peptide bond. The mutation of this
glutamic acid residue in MMP-7 can lead to reduction of
specific activity up to 1000-fold [2]. Another interesting
feature is the integrity of the 12 Å wide catalytic groove
produced by the combination of the five –stranded α
sheet, the catalytic β helix II, and the Met-turn loop
(Figure 1). Instead of using cysteine disulfide bridging, two
calcium and one or two structural zinc atoms are required
to maintain the correct architecture. Two homologous
EF-hand calcium-binding motifs and the triple His zinc-
binding motif stabilize the five-stranded β sheet [3]. The
third calcium in the X-ray crystal structure of the TIMP-1
/MMP-3 complex was located adjacent to the Met-turn
[4,5]. The specific importance of this structural calcium is
still unrevealed. The fourth-strand of this β sheet contri-
butes the major contact area for docking the natural
MMP inhibitors, the TIMPs [6,7].
An interesting question is - what is the minimum por-
tion of the enzyme that still possesses catalytic activity?”
It is known that in most MMPs, not only the propeptide
but also the hemopexin domain can be deleted without
effect on activity (e.g., stromelysin). Matrilysin, MMP-7,
is already “truncated”, and the active form consists onlyTable 1 Sequence alignment of two representatives of




Adamalysin II TMAHELGHNLGMEHDGK LRGASLCIMRPGLTPGR
Matrilysin AATHELGHSLGMGHSSD HSSDPNAVMYPTYGNGD
Only the sections containing the zinc-binding histidine residues and the Met-
loop areshown. The histidine zinc-ligands, the catalytically active glutamic acid
residue, the residue directly following the third His ligand, the conserved Met
residue, and the two positions after the Met are in.
a Pseudomonas aeruginosa alkaline proteinase.
b 3.4.24.11 protease.
PDB code: (ADAM: 2RJP[20], Astacin: 1QJI[21], Adamlysin II: 2AIG[22],
HumanMMP-7: 1MMR[3], P. aeruginosa alkaline protease: 1AKL[23], 3.4.24.11
protease: 1THL[10].)of a 180 residue catalytic domain. However, in the gelati-
nases this catalytic domain is divided by the insertion of
3 fibronectin-like repeats. The division leaves the active
zinc and sixty residues on the carboxyl side of the
‘break’. We decided to employ recombinant protein techni-
ques to generate the truncated form of rat matrilysin which
is lacking the five-stranded β sheet (N-domain) and to
address the following questions concerning the resulting
60-mer. First, is the helix B-Met-turn-helix C the minimum
domain required for activity; second, does this minimal do-
main still possess the original substrate recognition; and
third, in the absence of the five-stranded-β-sheet, can
matrilysin complex with its native inhibitor, TIMP, and syn-
thetic inhibitors?
Methods
Expression and purification of recombinant rat matrilysin
zinc-binding domain (ZBD) domain proteins in Escherichia
coli BL 21(DE3) cells
The rat cDNA containing zinc-binding domain (a.a. 212–
267) insert corresponding to human cDNA containing
zinc-binding domain (a.a. 188–247) of rat matrilysin was
synthesized by using a pair of primers, Zn-UMP 5’TCA-
CATATGGGAGTGAACTTCCTGTTT3’ and the Sp6
primer which is from the SP6 promoter region of
pGEM3Zf(+) in one-step PCR and sub cloned into the
Nde1 and BamH1 sites of PET3a vector (Novae). The
cDNA insert of the zinc-binding domain (ZBD) expres-
sion construct was completely sequenced by using the
Sequenase Version 2.0 Kit (U.S. Biochemical Corp.). The
expression plasmid was used to transform E. coli BL21
(DE3) cells (Novagen). Cells were cultured for 6 h
(OD600=0.2 ~ 0.4) followed by 2 hrs with IPTG. Cells
were collected, passed through a French press and centri-
fuged at 13,000 rpm for 20 mines. The pellets were
washed 3X with 10 ml of inclusion-body wash solution
(0.01% Triton X-100, 50 mM Tris, pH7.5). The pellets
were suspended in 8 M urea, 0.2 M NaCl, 50 mM Tris,
pH 7.5, 0.02% Na azide. After 48 hrs at 4 °C, the sample
was centrifuged. The soluble fraction was fractionated by
passing through a P30 molecular sieve chromatography
column (Pharmacia) in 8 M urea, 0.2 M NaCl, 50 mM
Tris, pH 7.5, 0.02% Na azide to partially separate the high
molecular weight and the 6 kDa ZBD, and then the frac-
tions contained 6 kDa ZBD were combined and applied to
a 2 ml zinc chelate-Sepharose 6LB column (Pharmacia).
This was washed with 30 ml buffer containing 8 M urea,
0.2 M Nacl, 50 mM Tris, pH 7.5, 0.02% Na azide. The
collected fractions were subjected to high resolution SDS-
PAGE analysis and followed by silver staining.
High resolution SDS-PAGE
The stock solutions for high resolution SDS-PAGE were
prepared as follows: Acryl/Bis (100 ml) contains 25.0 g
Figure 1 Structure comparison of Human MMP7 with metalloproteases. Details of the PDB structure codes of related proteins are as followed:
ADAM: 2RJP, Astacin: 1QJI, Adamlysin II: 2AIG, Human MMP-7: 1MMR, P. aeruginosa alkaline protease: 1AKL, 3.4.24.11 protease: 1THL. It is interesting to
notice the locations of the catalytic domain consisting of a red twisted β sheet as TAD and long yellow α helices which zinc-binding motif located on. All
the structures are viewed in approximately the same orientation for better comparisons. TADs are presented in red ribbons, and catalytic HLH were
presented in yellow ribbon. The main chains of the six metalloproteases are represented with ribbons in different colors. The Important motifs, such as
calcium, zinc and their binding residues, and inhibitors are presented with ball-and-stick style. The side-chains of crucial basic residues discussed in the text
are shown as colored sticks.
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12.1 g Tris (1 M), 3.76 g Glycine (0.5 M), 2.0 g SDS (4%),
pH 9.0; upper buffer (25 ml) contains 1.51 g Tris, pH 6.7,
1.4 ml 0.5 M EDTA, and 0.7 g SDS; running buffer
(300 ml) contains 3.63 g Tris, 3.38 g Glycine, 0.3 g SDS, pH
8,45, self-set, pre-SDS. For resolving the molecular weight
ranging between 2–100 kDa proteins, a 15% high resolution
running gel was prepared by mixing 6.0 ml Acryl/lBis,
2.0 ml lower buffer, 1.0 ml H2O, 1.0 ml 50% Glycerol, 10 μl;
TEMED, 100 μl; 10% APS. The mixture with running gel
solution was poured into the gel cast, leaving a 2.5 cm
space from the top for 30 minutes. The stacking gel solu-
tion containing a mixture of 1.6 ml Acryl/Bis, 1.4 ml upper
buffer, 6.0 ml H2O, 1.0 ml 50% Glycerol, 15 μl TEMED,
100 μl 10% APS was poured. The stacking gel was polyme-
rized for another 30 minutes. Samples were loaded into the
wells and run at 90 V in the presence of full strength
running buffer in the upper chamber, and 1; 1 dilution of
running buffer in the lower chamber.
Refolding of zinc binding domain
The purified and denatured (8 M urea) 6 kDa ZBD was
diluted drop wise 10-fold in ice-cold refolding buffer(20 mM Acetate, pH 5.6, 10 mM CaCl2, 1 μm ZnCl2,
0.2 mg/ml heparin and 0.05% Triton X-100). After 30
minutes, the sample was centrifuged at 14,000 rpm for
10 minutes to remove the insoluble portion. Storage of
soluble refolded protein was at −70 °C in 18% Glycerol.
Western blot
The protein samples were separated by SDS-PAGE, trans-
ferred to nitrocellulose membranes (BioRad). Then 0.1%
Tween-20 (TTBS) containing 5% non-fat milk was used to
block the membrane for 3 hrs at 24 °C. The first antibodies
(e.g., RM7-C and RM7-P) were applied at 4 °C overnight.
After 3X washing with TTBS/milk, the second antibody (e.
g., goat anti-rabbit IgG-alkaline phosphatase) was applied
for 2 hrs. Then the transblot was washed 3X with TTBS/
milk and stained with NBT/BCIP (Pierce).
Mca-peptide assay
For assay the proteolytic activities for the E Coli derived
purified refolded recombinant mini-Matrilysin(ZBD) pro-
teins, Enzyme assays were conducted at 37 °C using
50 mM Tris–HCl buffer, pH 7.5, containing 100 mM
NaCl and 10 mM CaCl2,1nM Zinc Chloride, 0.1% tween
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Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 (λex= 380 nm,
λem=460 nm) was first dissolved in DMSO and the solu-
tion was diluted to give a final concentration of 0.1 mM,
using the buffer described above. The fluorescence of 7-
amino-4-methyl-coumarin produced was monitored using
a Hitachi fluorescence spectrofluorimeter, model MPF-2A
, equipped with a recorder. The measurements were car-
ried out with excitation at 380 nm and emission at
460 nm. The fluorescence spectrofluorimeter was set to
zero with substrate in assay buffer. For each enzyme, the
initial rate of cleavage of Mca-Pro-Leu-Gly-Leu-Dpa-Ala-
Arg-NH2, measured over 10 to 15 minutes, Stopped
assays were made with the 0.1 M sodium acetate, pH 4.0
at different time points of interest [8]. The fluorescence
spectrofluorimeter was standardized so that at 10 μM so-
lution of MCA in 0.1% DMSO gave 1.0 relative fluore-
scence unit. 7-amino-4-methyl-coumarine is used as the
reference compound to make a standard curve to quanti-
tate the hydrolysis products from the reactions. The H-
Pro-Phe-Arg-AMC peptide is a non-cleavable substrate as
negative background control to standardize the instrument.
Amc-peptide assay
Enzyme assays were conducted at 37 °C in 50 mM
Tris–HCl buffer, pH 7.5, containing 100 mM NaCl and
10 mM CaCl2 in a total volume of 2.5 ml. The sub-
strate, H-Pro-Phe-Arg-AMC was first dissolved in
DMSO and the solution was diluted to give a final con-
centration of 0.1 mM in the buffer described above.
The reaction was started by the addition of 10 μl of enzyme
and the fluorescence of 7-amino-4-methyl-coumarin
produced was monitored using a fluorescence spectro-
fluorimeter. The measurements were carried out with exci-
tation at 380 nm and emission at 460 nm. The fluorescence
spectrofluorimeter was standardized so that at 10 μM solu-
tion of MCA in 0.1% DMSO gave 1.0 relative fluorescence
unit. 7-amino-4-methyl-coumarine is used as the reference
compound to make a standard curve to quantitate the
hydrolysis products from the reaction.
N-TIMP-1 and synthetic inhibitors inhibition assay
Synthetic fluorogenic peptide substrate, Mca-Pro-Leu
-Gly-Leu-Dpa-Ala-Arg-NH2, for MMP-7 [8] was used to
assay the ability of N-TIMP-1 and several synthetic inhi-
bitors, BB94 and SC44463 to inhibit recombinant ZBD.
Assay of the inhibition of recombinant ZBD and human
active MMP-7 by recombinant full length TIMP-1, N-
TIMP-1(gift from Dr. Keith Brew [6,9]) and synthetic
inhibitors was carried out by pre incubating the MMP
(0.1 to 1 nM) and TIMP (a series of concentrations) in
50 mM Tris–HCl, pH 7.5, containing 0.15 M NaCl,
10 mM CaCl2 and 0.02% Brij at 37 °C for 1 hr. The time
required for equilibration was determined by followingthe progress of inhibition after mixing MMPs and TIMP
at concentrations in the range used in the assay. An
aliquot (60 μl) of substrate (15 μM) was then added to
540 μl of the pre incubated MMP-TIMP mixture and ac-
tivity was measured at 37 °C by following product re-
lease with time.
CM-transferrin zymography
CM-transferrin (bovine), transferrin was reduced and
carboxymethylated as described by Nagase (1995). CM-
transferrin (0.3 mg/ml) was embedded in 12.5% SDS–
PAGE gel. Purified & refolded 6 kDa MMP-7 ZBD was
treated with sample buffer without dithiothreitol at room
temperature and electrophoreses until the dye-front was
near the bottom of the gel. Each gel was washed 5 times
with 50 ml 2.5% Triton X-100, 50 mM Tris, pH 7.5, 4 °C,
20 min each, to remove SDS and then 3 times with 50 ml
buffer plus 5 mMCaCl2. The gel was washed with 50 ml in-
cubation buffer (50 mM Tris, pH 7.5, 5 mM CaCl2) and
then incubated in 50 ml this buffer with added protease
inhibitors (50 mM each of Z-Phe-chloromethylketone,
Tosyl-Phe-chloromethylketone (ZPCK) and amino ethyl
benzenesulfonyl fluoride (PMSF)) for 18 h, 37 °C, with
gentle shaking. Gels were stained with 0.1% Coomassie blue
in 40% MeOH, 10% acetic acid, for 50 min, and destained
with 7% acetic acid. The gels were scanned and digitized
with a UVP analyzer and two dimensional intensities were
determined with the Gelbase program (Ultra Violet
Products, Upland, CA).
Molecular docking of SC44463, BB94 and phosphoramidon
SC44463, BB94 and phosphoramidon docking and data
analysis. BB94 is selected for positive binding and phos-
phoramidon for negative control on MMP7. The 3D struc-
tures of the human MMP7 protease [3] (PDB code:
1MMR) and thermolysin [10] (EC#: 3.4.24.11) ((PDB code:
1THL) were retrieved from the Protein Data Bank.
PRODRG program (http://davapc1.bioch.dundee.ac.uk/
programs/prodrg/) were used to generate the coordinate
and topology files of SC44463 [11,12], BB94 [13-15] and
Phosphoramidon [16,17]. SC44463, BB94 and Phosphora-
midon were computationally docked into the 3D structure
of the human MMP7 protease and thermolysin using the
docking program GOLD [18] (version 2.1.2; Genetic
Optimization for Ligand Docking, CCDC, Cambridge, UK)
or PPDOCK program (http://140.112.135.49/ppdock/).
GOLD operates with a genetic search algorithm and allows
for complete ligand and partial-binding site flexibility [18].
Because SC44463, BB94 and Phosphoramidon may be the
inhibitors of the catalytic centers which zinc-binding motif
located in helix-2, we defined the binding site to the inhibi-
tor as the putative znic catalytic pocket. The results were
ranked by GOLD’s scoring function which is a molecular
mechanics-like function with four terms based on
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der Waals energy, ligand internal van der Waals energy,
and ligand torsional strain. The 100 steps of energy
minimization of the best docking structure were carried
out using the CNS programs [19]. The interactions
between SC44666 and the human MMP7 protease were
analyzed and illustrated by Discovery Studio 3.0 (Accelrys
Software Inc.) and Chimera (The University of California).
Results
Structure comparison of human MMP7 with
metalloproteases
We take some metalloproteases to compare with human
MMP7 [3] as fallowing: ADAM [20], Astacin [21],
Adamlysin II [22], P. aeruginosa alkaline protease [23],
2.4.24.11 protease [10]. It is clear to show that the loca-
tions of the catalytic domain consisting of a twisted red
β sheet as TAD and long yellow α helices which zinc-
binding motif located on (Figure 1). They have similar
folding structures which are made up of two domains:
an “upper” N-domain comprising the N-terminal part of
the polypeptide chains forming the five-stranded β sheet
and a lower C-domain form a α-helix-loop-α-helix
packing. α-Helices shown in yellow, β-strands shown in
red, and other parts of the polypeptide chains in colors.
All six molecules are shown with the central active
center cleft lying horizontally in the paper plane after
superimposed for structural comparison. Six metallo-
proteases structure share the conserved HLH folding
(domain) with different length of loops.
This stretch from residue 188–247 of human MMP7
could be considered the minimum sequence required for
enzymatic processes, substrate analogue inhibitor docking,
and substrate recognition. The three-dimensional struc-
tures of the adamalysin II from rattle snake venom (repro-
lysin), alkaline proteases from Pseudomonas aeruginosa
(serralysin), and astacin from crayfish are topologically simi-
lar with respect to the five-stranded-β-sheet (N-domain)
and three α-helices (C-domain) arranged in typical sequen-
tial order (Figure 1) [24,25].
The strands sIII and sIV (β sheets) forming the upper
wall of the active cleft are quite conserved in length and
position in the metzincin family [2]; the loop connecting
them is quite different in all four subclass members. In the
matrixins, the sIII-sIV linker exhibits an S-shape, looping
around a structural zinc ion and a tightly bound calcium
ion. All six enzymes show an almost identical active site en-
vironment (Figure 1) [24]. Helix hB contains the short con-
sensus motif HEXXH (Table 1). The two histidine zinc
ligands are separated by a single helix turn, which allows a
concerted approach by two flanking imidazoles toward the
catalytic zinc. The carboxylate group of the intermediate
glutamic acid is involved in the fixation of a zinc-bound
water molecule (Table 1, Figure 1). The active site helix ofthe metazincin is terminated at an invariant glycine residue,
three residues away from the second histidine zinc ligand.
Subsequently, another three residues after the glycine, the
third histidine metal ligand is projecting toward the cata-
lytic zinc from below. The most remarkable 1, 4 tight turn
of virtually identical conformation and position relative to
the catalytic zinc, called the Met-turn, appears to be essen-
tial for the structural integrity of the zinc-binding active site
of the metzincin family. Following the Met-turn is the C-
terminal helix hC. The helix hC is a potential amphipathic
helix participating in lining the active cleft and connecting
the N-domain through salt bridge formation between the
Asp in the hC and Trp in the N-terminal [24,26]. Although
there is an almost identical active site environment in the
four groups of the metzincin family, each still exhibits
distinct substrate specificity. TAD may be responsible for
additional regulation and unfolding substrate for MMP7.
Construction, expression and purification of E.Coli BL21(DE3)
derived recombinant 6 kDa catalytic zinc-binding domain
(ZBD) proteins
The expected molecular weight protein of 6 kDa appears in
the total extract of BL21 (DE3). PET3a.ZBD cells after 2
hour IPTG induction (Figure 2, lane 4), but not in the total
cell extracts of negative control BL21 (DE3).PET3a cells
after 2 hour IPTG induction (Figure 2, lane 5) or before
IPTG induction of transformed cells (Figure 2, lane 3). The
E.coli derived recombinant ZBD predominantly appeared
in the insoluble fraction called inclusion bodies (Figure 2,
lane7). The 8 M Urea solubilized inclusion bodies
(Figure 3A, lane S2) were concentrated 10 fold (Figure 3A,
lane S1) and loaded onto the molecular sieve chromato-
graphy P30 and partial separating the high molecular
weight (Figure 3A, lane 12& 13) and the 6 kDa ZBD
(Figure 3A, lane 14–17). In order to further purify 6 kDa
ZBD, the P30 column were used and the fractions contai-
ning 6 kDa ZBD were pooled together (Figure 3B, lane S)
and then applied to a 2 ml zinc chelate-Sepharose 6LB
column (Pharmacia). In the fall-through from the zinc
column fractions, there is a trace of a 6 kDa bacterial pro-
tein (Figure 3B, lane F1 and F2). Washing with 30 ml
column-wash buffer was followed by elution of the bound
ZBD with pH 4.5 buffer (Figure 3B, lane E3-E8). Greater
than 95% purity of recombinant ZBD was shown in the
silver stained high resolution SDS-PAGE.
Western blot assay for recombinant 6 kDa ZBD
The molecular weight 6 kDa deduced from 60 amino
acids in this fragment of the purified ZBD was further
confirmed by western blot with anti-MMP-7
peptide255-267(RM7-C) and anti-MMP-7 peptide43 55
(RM7-P) polyclonal antibodies [27]. Each polyclonal
antibody showed no cross-reaction with the opposite
peptide conjugated to BSA (Figure 4A, lane N & C) or
Figure 2 The E. coli BL21 (DE3). PET3a ZBD Expression Profile
of Recombinant ZBD. E. coli BL21 (DE3). PET3a ZBD transformed
cells were grown at 37 0 C to OD600 reading 0.2 ~ 0.4, 10ul of total
cell extracts from 200 μl of cells solibilized in 1% SDS sample buffer
as control for before IPTG induction were prepared as method
described (lane 3). After 2 hour 0.8 mM IPTG induction, 10ul of total
cell extracts from 100 ul of cells were prepared as after IPTG
incubation (lane 4). 10ul of total cell extracts from 100 μl of 2 hours
IPTG inducing PET 3a mock transformation BL21 (DE3) cells was
prepared as negative control (lane 5). The pellet after French press
and inclusion bodies 0.1% triton X-100 wash steps were prepared
(lane 7). Lane 1: Molecular weight standard; Lane2 and 6: Blank. Figure 3 Purification of Recombinant ZBD. Panel A: shows the
silver staining for the high resolution SDS-PAGE analysis for the
purification fraction profile from the P30 molecular sieve
chromatography. The 8 M Urea 50 mM Tris pH 7.5 solubilized
inclusion bodies (lane S2) was concentrated 10 fold (laneS1) as the
start material before loading onto P30 column. 15 μl of the fractions
gave OD280 reading were subjected to high resolution SDS-PAGE
analysis (lane 10–17). The combined fractions #14-#15 (lane p) were
concentrated 10 fold (lane pc). Panel B: shows the silver staining for
the high resolution SDS-PAGE analysis for the purification fraction
profile from the fractions zinc-chelate chromatography. Combining
the partial purified fractions containing ZBD from P30 collumn (lane S)
were subjected to the zinc-chelate affinity. The unbound fall-through
fractions (lane F1 and F2) and the wash buffer fractions are shown
(lane W1 and W2). The bound ZBD was eluted with pH 4.5 buffer and
the low pH eluted fractions (lane E3-E10).
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zinc binding region of rat matrilysin can only react with
anti-MMP-7 peptide255-257 polyclonal antibody (RM7-
C) (Figure 4A, right panel lane Z), but not anti-MMP-7
peptidere43-55(RM7-P) (Figure 4A, left panel lane Z).
This immunodetection confirmed that the zinc-chelate
affinity-purified 6 kDa protein is the expected recombinant
ZBD protein and the fact that there is no trace of cross-
reactivity shown by using anti-MMP-7 peptide43-55 indi-
cates that 6 kDa proteins are not derived from the N-
terminal part of rat matrilysin, instead of being produced
by autolysis post activation (Figure 4A, right panel lane A).
Triton X-100 and heparin are accessory factors folding
recombinant ZBD in vitro
Unlike the inclusion bodies of recombinant proMMP-7 or
active MMP-7 which can be partially purified by several
washing with Tris 50 mM pH 7.5, 0.25% Triton X-100 and
5 mM DTT, the inclusion bodies of recombinant ZBD are
easily solubilized by 0..25% Triton X-100 and demonstrate
MMP activity (data not shown). This is quite a unique
property of the inclusion bodies of recombinant ZBD. In
most cases of recombinant proteins over-expressed in BL21
(DE3), it usually requires strong chaotropic reagent, such as
4~8 M Urea or 4 M Guanidine, to solubilize the inclusion
bodies. Surprisingly, we found that 0.05% Triton X-100 is
enough to solubilize the inclusion bodies of recombinantZBD (data not shown). This raised the possibility that
Triton X-100 might also be an accessory factor in the fol-
ding process of ZBD, especially since it is frequently added
to various MMPs as a stabilizer. Interestingly, 0.25% Triton
X-100 had been used in the zymography procedure to re-
move the SDS and assist folding in gels. My previous
studies also showed that heparin can enhance the acti-
vities of MMPs by stabilizing the enzymes. The result
from the refolding test showed that Triton X-100 was a
better accessory folding factor than heparin, but the
combination of 0.05% Triton X-100 and 0.3 mg/ml
heparin gave the best refolding activities in the Mca-
peptide assay (Figure 5A). The instability appeared to
be the major factor concerned in the refolding process,
Figure 4 Western Blot Analysis for ZBD. The polyclonal
antibodies, anti-propeptide (RM7-P) and anti-C-terminal peptide
(RM7-C), were used to detect the final purified fraction of ZBD.
Panel A left: The transblot was reacted with RM7-P anti serum
which specifically recognizes the proenzyme (lane P1 and P2) and
the peptide22-34 conjugated BSA (lane N); Panel A right : The
transblot was reacted with RM7-C anti serum which recognizes all
populations of recombinant MMP-7 and the peptide238-247
conjugated BSA (lane C), except for the peptide22-34 conjugated to
BSA (lane N). Both antibodies have no cross-reactivities for the BSA
carrier (laneB) or each other. Panel B: The silver staining for the high
resolution SDS-PAGE shows the sample loading profile. Mw:
Molecular weight standard; P1 and P2: proMMP-7; A: all populations
of activated MMP-7. Z: recombinant CZBD; N: peptide22-34
conjugated BSA; C: the peptide238-247 conjugated BSA. B: BSA.
Figure 5 Combination of 0.05% Triton and 0.2 mg/ml heparin
give the optimal refolding activities to cleave the synthetic
coumarin-labelled peptide substrate, Mca-Pro-Leu-Gly-Leu-Dpa-
Ala-Arg-NH2. Panel A: Shows the refolded ZBD activities increased in
dose-dependent manner. In the absence of the refolding accessory
factors, Triton X-100 and heparin. The significant reduced activities in
the high-concentration (> 100 μg/ml) was observed which could be
due to autolysis. Panel B: Under 37 °C incubation for 18 hours, Triton
X-100 and heparin can prevent the activity loss. (All experiments were
repeated at two batch of purification and refolding preparation and
data collected from a representative experiments).
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when the concentration of ZBD reached 40 ng/per
assay, the activities of ZBD decreased dramatically. In
the next test, after challenging with 18 hrs 37 °C pre in-
cubation, the loss of activity of refolded enzyme for
each refolding condition was measured by the Mca-
peptide assay. There is only 13% of total activity lost in the
presence of Triton X-100 and heparin. Heparin seemed to
be a more important factor and did a better job than TritonX-100, 23% vs 37% lost of total activity (Figure 5B). In the
absence of both factors, 52% of total activity was lost after
18 hrs 37 °C pre incubation (Figure 5B).The helix-loop-helix, 6 kDa ZBD, provides sufficient
structure for substrate and inhibitor recognitions
The activity was determined by hydrolysis of the coumarin
labeled-peptide, Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2
which has been reported to be a very sensitive substrate for
matrilysin. Another peptide substrate, H-Pro-Phe-Arg-
AMC, which has been reported a sensitive substrate for
plasminogen was used to test the substrate specificity of
6 kDa ZBD. The results revealed that the activities are in-
creasing in dose-dependent manner against Mca peptide
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http://www.jbiomedsci.com/content/19/1/54(Figure 6A), but not Amc-peptide (data not shown). The
buffer alone or enzyme itself did not give any significant
intrinsic fluorescence reading. The kcat/Km is about
106 M-1 s-1determined by hydrolysis of Mca-peptide sub-
strate, which is about 400~ 500 fold less than the wild
type activity. Interestingly, according to the X-ray crystal
structure even though there is no the third calcium
revealed in the catalytic zinc-binding domain, 5 mM
calcium and 1 μM zinc are required for optimal catalytic
activity. Refolded 6 kDa ZBD continued to catalyze the
hydrolysis of the fluorogenic peptide substrate over the
entire time of the assay. The activity increased in a time-
dependent manner (Figure 6B), but the substrate alone
showed no digestion. However wild-type matrilysin can
completely digest all the substrate within 2 hrs. Although
6 kDa ZBD was able to cleave the peptide substrate andFigure 6 Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 assay for characteriz
refolded ZBD shows increasing enzymatic activity in dose-dependent mann
situation. Panel B: approximately 6 ng/ml refolded ZBD shows the increasi
during overnight incubation. Panel C: Recombinant ZBD can be inhibited
SC44463 and CoCl2, but not b6 250 nM Phosphoramidon. (All experiments
and data collected from a representative experiments).kept its substrate specificity it is much less efficient than
the full length active matrilysin. This result strongly
suggests that the C-domain, helix-Met-turn-helix, lower
part of the active matrilysin is the minimum structural
element for substrate recognition and catalytic activities
and the N-domain, five-stranded β sheet, upper portion is
re1uired for efficient substrate hydrolysis. The protein
substrate, CM-transferrin, cleavages seem dependent on
the hexamer and octamer formations of 6 kDa in the pre-
sence of heparin sulfate and triton X-100 revealed in CM-
transferrin zymographic analysis (Figure 7) [27,28]
6 kDa ZBD is inhibited by EDTA and synthetic inhibitors, but
N-TIMP-2 inhibits ZBD less effective than it does wild type
This activity could be inhibited by 10 mM EDTA, 1 mM
CoCl2 and MMP substrate analogue synthetic inhibitors,ation of refolded ZBD. Panel A: Under the optimized conditions, the
er. No significant activity loss was found in the high concentration
ng activity during the time course study and no significant activity loss
by 10 nM EDTA, 1 mM CoCl2 and synthetic inhibitors, 50 nM BB94 &
were repeated at two batch of purification and refolding preparation
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http://www.jbiomedsci.com/content/19/1/54SC44463 and BB94, but not by the 24.11 metalloendopepti-
dase (neprilysin) inhibitor, phosphoramidon, or serine pro-
tease inhibitors, such as ZPCK [29]. The concentrations of
SC44463 and BB94 required inhibiting 50% of the enzyme
activities were about 5 nM. This value is similar to the IC50
for active MMP-7 (Figure 7C). Full length TIMP-1 or N-
TIMP-1 did not inhibit ZBD as efficiently as full-length
active matrilysin. However, a 25-fold higher concentration
of N-TIMP-2 can completely inhibit ZBD (data not
shown).
Molecular docking of SC44666
SC44463, (N4-hydroxy-N1-[1 S [(4-methoxphenyl)me-
thyl]-2-(methylamino)-2 -oxoethyl]- 2R-(2-methylpropyl)
butane-diamide), A powerful synthetic inhibitor of Matri-
lysin and collagenases is reported to inhibit ovulation in
perfused rat ovaries at 25 nM [30]. From our previous
study, sc44463 is a potent inhibitor with IC50 ~10nM
[30,31]. We decide to use sc44463 to perform the docking
studies for Zinc-Dependent Proteolytic Domain- Helix-
Loop-Helix Catalytic Zinc Binding Domain (ZBD) for
MMP-7.
Phosphoramidon were not good for docking into MMP7
as negative control for selectivity. SC44463 can successfully
dock into MMP7 in multiple residues (in pink) Ala187,
Ala184, Phe185, His 124, Ala 183 which contribute up to
70% contact inter phase compared to the whole enzyme. In
BB94 case, the results of docking only shown weaker
hydrophobic interaction than SC44463 with TAD domain
(Figure 8 & 9B,3). There is no pi-pi interaction between
BB94 and MMP7 as pi-pi interaction between SC44463
and Tyr73 in MMP-7 (Figure 8). The hydroxamate group,
HONHCO-CH2C-, of sc44463 contributes to occupy the
catalytic zinc to prevent from ionizing H2O molecules.
MMP7,a zinc dependent metallopotease, the proteolytic
catalytic divalent cation zinc in the active center is involved
in the peptide bonds cleavage through the transientFigure 7 The polymerization of the 6 kDa ZBD of MMP-7 in pentame
towards to the CM-transferrin substrate in CM-transferrin zymograph
co-polymerized with SDS-PAGE as a substrate gel for analyzing the MMP-7electron acceptor for the peptide bond attack by the ionized
H2O which Glu-121 donate a pair of electron (Figure 8A).
In this study, we try to define the minienzyme of metzin-
cin super-family. The minienzyme of human MMP7 as
ZBD can fold and maintain its catalytic activity. Due to the
above description, the mini-enzyme can provide the plat-
form for performing screen or virtual screen to discover
broad range of inhibitors. Nevertheless, the discovery of
highly selective small molecule protease inhibitors across a
wide variety of protease is still achievable. For example,
neprilysin (neutral endopeptidase 24.11; NEP) inhibitor,
phosphoramidon, obtained by analogs with methyl or ethyl
substitutions, was relatively not potent [32]. The docking
simulation of SC44463 revealed that this compound
blocked the direction of the peptide chain in contact with
the active site is in the reverse direction of that seen in
complex of stromelysin with synthetic inhibitors [33]. As
shown in Figure 8, we found that the SC44463 coordinated
the zinc ion and formed pi-pi interaction with side chains
of His-124 (HLH) and Tyr-73 (TAD), the oxygen on the
main chains of Glu-121 (HLH) of human MMP-7. In
addition, Ala-83 (TAD), Ala-85 (TAD), Ala-87 (TAD)
donated hydrophobic interaction to SC44463. Thus, the
drug docking data of human MMP-7 indicated that
SC44463 was a good lead compound for the inhibiting the
activity of human MMP-7 through its competitive action
with peptide chain pocket. In the discovery and develop-
ment of metzincin inhibitors, some inhibitors have been
approved and successfully targeted to different therapeutic
targets in various protease [34]. Our results presented here
show that SC44463 was able to suppress the proteolytic ac-
tivity of human MMP-7 and 6 kDa mini MMP-7. Based on
the modeling results, further refinement of the potency and
selectivity of SC44463 can be further studied by the modifi-
cations of some critical functional groups of SC44463 for
rational analog- based searching more potent specific inhi-
bitors for this helix B Met loop-helix C folding domain.r and Octamer demonstrate the significant proteolytic activities
ic assay. 300 μg of craboxylmethylated transferrin (CM-transferrin) was
activities in situ.
Figure 8 Molecular docking of SC44463 in Human MMP7. (A) A 2D diagram of the details of the SC44463 binding environment. The SC44463 was
docked onto Human MMP7. Illustration of amino acid contacted to the SC44463 in Human MMP7. SC44463 contacted to TAD (57–114) in the left part
(Tyr73, Ala83, Ala85, Ala87) and to HLH (114–173) in the right part (His120, Glu 121, His124, His138, Znic ion). (B) Overall illustration of molecular docking of
SC44463 in Human MMP7. HLH shown in yellow, TAD shown in red, and other parts of the polypeptide chains in rice white. The binding complex is
shown in the standard orientation, i.e. with the cental active center cleft lying horizontally in the paper plane. Zinc ion, three binding histidines and
SC44463 are presented with ball and stick model. (C) TAD and HLH of binding complex are shown as 30% transparency solid surface colored with surface
charge. SC44463 is presented with stick and the complex in rice white ribbon. (D) Only HLH of binding complex are shown as 30% transparency solid
surface colored with surface charge. It is interesting to notice that the major contact between SC44463 and Human MMP7 are in the HLH area with salt
bridge, hydrogen bond and pi-pi interaction. SC44463 is presented with stick and the complex in rice white ribbon.
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compound to develop more potent selective inhibitor for
MMP-7.
Discussion
A widely-accepted concept is that the full-length active do-
main of MMP is the minimum structure required for full
catalytic activity and affinity for TIMP. This appears to be
true, but the present studies show considerable residual ac-
tivity in the truncated enzyme. The characteristic consensus
motif HEXXHXXGXXH and the Met-turn motif (Table 1),
P/Y-XMBX (B: Bulky residues), are the major elements
arranged in the common topological structure helix-loop-
helix forming the lower half C-terminal portion of the 60
residue domain. [25,35-37]. by adding the upper half five-
stranded β sheet (N-domain) (Figure 1), the active center
cleft is completed (Figure 8C-D). The exact function of the
C-portion which possesses the major catalytic elements is
still unknown. It is important to address the molecular andstructural function of this helix-Met turn-helix motif, which
contains the catalytic zinc element. In evolution, this funda-
mental building block was augmented by additional gene
with the metzincin super-family to give rise ultimately to
the present four subclasses. In this report, the folded
recombinant ZBD corresponding to the C-portion demon-
strates that it possesses the abilities of substrate recognition,
catalytic hydrolysis and inhibitor binding (Figure 8A & 9).
At this point, it will be fair to call this ZBD fragment a zinc
binding domain with catalytic function [35].
However, the reasons for the loss of catalytic hydrolysis
efficiency compared to full-length active enzyme could be
that the five-stranded β sheet (N-domain) is important in
contributing hydrophobicity to the active cleft. A common
feature for the active center of most enzymes is the non-
polar environment in the active center. The hypothesis, as
introduced by Cohen et al. 1970 and Crosby et al. 1970
[38,39], suggested that enzyme active sites becomes basi-
cally non-polar after removal of water molecules and that
Figure 9 Comparison docking results of SC44463 in Human MMP7 and in 3.4.24.11 protease and other protease drugs. (A) The structure
of the SC44463, BB94 amd Phosphoramidon is presented as colored stick model. (B) The SC44463 was docked onto human MMP7. Illustration of three
histidine (His120, His124, His138) of human MMP7 in SC44463-Huaman MMP-7 complex. SC44463 is presented as rice white stick model and HLH of
human MMP7 is shown as yellow ribbon. CCT-Thermolysin complex (PDB code: 1THL). The N-(<1-[(2 S)-2-carboxy-4-phenylbutyl]
cyclopentyl> carbonyl)-L-tryptophan (CCT) as 3.4.24.11 protease inhibitor is presented as rice white stick model and SC44463 is presented as sky blue
stick model. It should be notice that SC44463 could not dock in to 3.4.24.11 protease very well. The huamn MMP7 is presented with ribbon model,
HLH shown in yellow, TAD shown in red. The docking result of SC44463-Huaman MMP-7 complex and BB94 shows that the pi-pi and hydrophobic
interaction of SC44463 is better than BB94. The SC44463 is presented as sky blue stick model and BB94 is presented as rice white stick model.
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http://www.jbiomedsci.com/content/19/1/54such non-polar sites help in accelerating enzymatic reac-
tions. Applying this hypothetical concept of desolvation
Kcat contribution to the situation of this “naked” active
center of 6 kDa ZBD, it is not difficult to imagine that the
loss of the N-domain five stranded β sheet makes the ac-
tive center of C-domain completely exposed to a polar en-
vironment which does not favor the desolvation process
and reduces the catalytic hydrolysis efficiency by two to
three orders of magnitude. The contribution of N-domain
could be offering the hydrophobicity to the active cleft
and helping the desolvation process during the catalytic
hydrolysis of substrate. 0.025% Triton X-100 could take
the place of the N-domain function, which enhances the
hydrophobicity of the active center, helps the desolvation
process and enhances the catalytic hydrolysis. Interest-
ingly, ZBD can only digest the intact protein substrate in
polymer forms, such as CM-transferrin, but can digestpeptides efficiently. One explanation is that this evidence
implies that the “naked” active centers of ZBD are buried
inside the non-polar environment of Triton X-100 micelle
and the peptide substrates can be more easily infused into
this micelle and become more accessible for ZBD to
hydrolyze than intact protein substrates do. The other ex-
planation is that the helix-loop-helix zinc binding catalytic
motif forming the smallest peptide bound cleavage folding
unit, however, the rest part of active MMP-7(~19 kDa)
facilitates protein-protein interactions to induce conform-
ational changes to expose the cleavable peptide region
which could be buried in the intact protein substrates.
However, this is purely hypothetical explanation. Another
interesting observation regarding the requirement for cal-
cium for activity, which is contradictory to the X-ray crys-
tal structure of active matrilysin [3] needs to be further
addressed in the near future.
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The helix B-Met loop-helix C folding conserved in metallo-
protease metzincin super family is able to facilitate proteo-
lytic catalysis for specific peptide substrate and inhibitor
recognition. Triton X-100 plus heparin sulfate is critical for
the refolding this 6 kDa helix B-Met loop-helix C domain
and also reveal the functional active hexamer and octamer
of the mini MMP-7 complex in CM-transferrin zymogra-
phy. 6 kDa mini MMP-7 through autolysis of proMMP-7 is
the smallest metalloprotease in living world.
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